Immune Repertoire Sequencing Market Explore Future Growth 2018-2026 by Global Top Players – Thermo Fisher Scietific, Illumina, ArcherDX, Roche Holding AG, Juno Therapeutics, Pacific Biosciences, CD Genomics, Atreca, Adaptive Biotechnologies

Coherent Market Insights has announced the addition of the “Immune Repertoire Sequencing Market Size Status and Forecast 2026”, The report classifies the global Immune Repertoire Sequencing Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Immune Repertoire Sequencing Speaker market, analyzes and researches the Immune Repertoire Sequencing Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Thermo Fisher Scietific, Illumina, ArcherDX, Roche Holding AG, Juno Therapeutics, Pacific Biosciences, CD Genomics, Atreca, Adaptive Biotechnologies

Request a sample copy of immune repertoire sequencing market : https://www.coherentmarketinsights.com/insight/request-sample/1517

Immune repertoire refers to the sub-type proteins an organism’s immune system creates. Immune systems in vertebrates have six key types of proteins namely: immunoglobulin (2) and T cell receptors (4). Immune repertoire sequencing enables researchers and scientist to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy.

Increasing research and development and launches of novel products by key players in market is expected to be the major driving force for growth of global immune repertoire sequencing market in the near future.

Increasing research on immune repertoire sequencing is expected to create a conducive environment for growth of immune repertoire sequencing market in the near future. Recently, immune repertoire sequencing has been applied for the development of cancer biomarkers and immunotherapies. Therefore, increasing prevalence of cancer is expected to positively drive growth of immune repertoire sequencing market. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. Moreover, the number of people suffering from cancer is expected to reach to 19 million by 2024. According to the Cancer Atlas, 2012, about 1.1 million new cancer cases and 600,000 cancer deaths are reported annually in Latin America and the Caribbean, where lung cancer is the leading cause of cancer death for both sexes. According to the World Health Organization (WHO), around 555,318 new cases of cancer were reported in the Middle East, in 2012. The region is expected to witness the highest relative increase in cancer cases globally, and it is expected to reach up to 961,098 by 2030.

By Product Type

Instruments
Reagents and Kits

By Application

Cancer Immunotherapy
Infectious Disease
Asthma And Allergy
Biomarker Discovery
Organ Transplant
Immune Response
Autoimmune Diseases
Others

By End User

Diagnostic Labs
Biopharmaceutical Companies
Research Institutes
Others

By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

North America is expected to hold a dominant position in global immune repertoire sequencing market, over the forecast period. This is owing to high presence of key players in the region. These players are increasingly focusing on development of novel technology for immune repertoire sequencing. For instance, Illumina Inc., Thermo Fisher Scientific, Pacific Biosciences, CD Genomics are the key players in the North America market. In 2017, a U.S.-based 10x Genomics Inc. added a new B-Cell and 5’unbiased enrichment kit to its chromium immune repertoire profiling solution or immune repertoire sequencing. Company has launched its new product at the 67th Annual Meeting of the American Society of Human Genetics (ASHG) held at Orlando, Florida in 2017. Furthermore, Europe, and Asia Pacific regions are also expected to show a rapid growth in immune repertoire sequencing market, due to increasing usage of immune repertoire sequencing in oncology research for the development of biomarkers and immunotherapies.

Major players in the market are involved in strategic partnership and collaborations, in order to develop and provide immune repertoire sequencing services to customers. For instance, in March 2018, ArcherDX Inc. and Ambry Genetics entered into strategic partnership to provide immune repertoire sequencing services to biopharmaceutical customers. As per the partnership agreement, Ambry Genetics will use ArcherDX's Immunoverse and VariantPlex next-generation sequencing assays for immune repertoire sequencing.

Else place an Inquire before Purchase “Immune Repertoire Sequencing Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1517

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.